Alnylam Pharmaceuticals, Inc.

ALNY

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001178670

A

strongest fifth of 370 graded peers in healthcare

rank 64 of 370; percentile 17.1; sampling error 2.5 points; lower is stronger

A B C D E

A, the bull



Scoreboard	
Profitability	B percentile 37.0
Solvency	C percentile 48.0
Growth and financing	B percentile 27.5
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $5.0B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress, fortress balance sheet
Inputs computable	9 of 14
Graded from	filings received through Feb 12, 2026 255 days before the rescan; latest periodic filing 10-Q received Jul 30, 2026
Last close	$223.95 2026-10-23; market equity $30.0B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 12, 2026

Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, the Company, we, our or us) is a global commercial-stage biopharmaceutical company developing novel therapeutics based on ribonucleic acid interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. By harnessing the RNAi pathway, we have pioneered a new class of innovative medicines, known as RNAi therapeutics.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 37.0						
Gross profitability	61.1%	32.3%		15.5	368	2025-12-31
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	(4.6%)	(6.6%)		63.0	807	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	1.8 pts	2.8 pts	32.4	242	2025-12-31
Solvency, sleeve percentile 48.0					
Twelve-month failure probability	not computable	0.07%			
liabilities and a nearby cover-page share count are required at 2026-03-31					
Altman Z double-prime	(0.11)	(0.33)	37.3	752	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	2.76x	2.94x	58.7	834	2025-12-31
Growth and financing, sleeve percentile 27.5					
Revenue growth, three-year compound	53.0%	10.1%	12.9	413	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	98.4%	37.1%	33.0	104	2025-12-31
Asset growth, three years	11.9%	2.1%	29.6	700	2025-12-31
Net share issuance, one year	2.4%	2.5%	34.5	636	2026-02-06

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
59	Vertex Pharmaceuticals Inc. MA (VRTX)	15.7	A	
60	RxSight, Inc. (RXST)	16.0	A	fortress balance sheet
61	Ensign Group, Inc. (ENSG)	16.3	A	fortress balance sheet
62	Definium Therapeutics, Inc. (DFTX)	16.5	A	dilution
63	Natures Sunshine Products Inc. (NATR)	16.8	A	fortress balance sheet
64	Alnylam Pharmaceuticals, Inc. (ALNY)	17.1	A	
65	Acadia Pharmaceuticals Inc. (ACAD)	17.3	A	
66	Aurinia Pharmaceuticals Inc. (AUPH)	17.6	A/B	
67	UFP Technologies Inc. (UFPT)	17.9	A/B	
68	Conmed Corp. (CNMD)	18.2	A/B	
69	Dexcom Inc. (DXCM)	18.4	A/B	fortress balance sheet

What the price implies

at the 2026-10-23 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(47.2%)	7.7%	15
Distance from 52-week high	(53.5%)	(31.4%)	25
EBIT to enterprise value	1.7%	(1.5%)	60
Free cash flow yield	1.6%	(1.0%)	63
Book value to price	0.05	0.28	18
Sales to price	0.12	0.30	30

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Composite equity issuance, five years	13.4%	20.5%	44
Relative strength against the sector, log excess return	(0.85)	(0.14)	15

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$1.7B
Operating cash flow, four quarters	$524.1M
Months of runway	not finite
Days since last periodic filing	87 (10-Q received Jul 30, 2026)
Median daily dollar volume, 63 sessions	$363.2M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.7B	2025-12-31	2026-02-12	10-K	26-007497
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$677.2M	2025-12-31	2026-02-12	10-K	26-007497
3	assets	us-gaap:Assets	$5.0B	2025-12-31	2026-02-12	10-K	26-007497
4	net income	us-gaap:NetIncomeLoss	$313.7M	2025-12-31	2026-02-12	10-K	26-007497
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$524.1M	2025-12-31	2026-02-12	10-K	26-007497
6	assets	us-gaap:Assets	$4.2B	2024-12-31	2026-02-12	10-K	26-007497
7	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.2B	2024-12-31	2026-02-12	10-K	26-007497
8	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$306.5M	2024-12-31	2026-02-12	10-K	26-007497
9	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.8B	2023-12-31	2026-02-12	10-K	26-007497
10	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$268.2M	2023-12-31	2026-02-12	10-K	26-007497
11	revenue	us-gaap:Revenues	$1.0B	2022-12-31	2023-02-23	10-K	23-000005
12	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$140.2M	2022-12-31	2025-02-13	10-K	25-000026
13	revenue	us-gaap:Revenues	$844.3M	2021-12-31	2023-02-23	10-K	23-000005
14	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$115.0M	2021-12-31	2024-02-15	10-K	24-000008
15	current assets	us-gaap:AssetsCurrent	$4.1B	2025-12-31	2026-02-12	10-K	26-007497
16	current liabilities	us-gaap:LiabilitiesCurrent	$1.5B	2025-12-31	2026-02-12	10-K	26-007497
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$6.7B	2025-12-31	2026-02-12	10-K	26-007497
18	operating income	us-gaap:OperatingIncomeLoss	$501.6M	2025-12-31	2026-02-12	10-K	26-007497
19	book equity	us-gaap:StockholdersEquity	$789.2M	2025-12-31	2026-02-12	10-K	26-007497
20	liabilities	us-gaap:Liabilities	$4.2B	2025-12-31	2026-02-12	10-K	26-007497
21	operating income	us-gaap:OperatingIncomeLoss	-$282.2M	2023-12-31	2026-02-12	10-K	26-007497
22	interest expense	us-gaap:InterestExpense	$121.2M	2023-12-31	2024-02-15	10-K	24-000008
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$58.7M	2025-12-31	2026-02-12	10-K	26-007497
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$8.3M	2024-12-31	2026-02-12	10-K	26-007497
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$34.3M	2024-12-31	2026-02-12	10-K	26-007497
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$104.2M	2023-12-31	2026-02-12	10-K	26-007497
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$62.2M	2023-12-31	2026-02-12	10-K	26-007497
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$541.3M	2022-12-31	2025-02-13	10-K	25-000026
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$72.1M	2022-12-31	2025-02-13	10-K	25-000026

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

30	depreciation amortization	us-gaap:Depreciation	$54.8M	2025-12-31	2026-02-12	10-K	26-007497
31	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$323.2M	2025-12-31	2026-02-12	10-K	26-007497
32	income tax	us-gaap:IncomeTaxExpenseBenefit	$9.4M	2025-12-31	2026-02-12	10-K	26-007497
33	current assets	us-gaap:AssetsCurrent	$3.3B	2024-12-31	2026-02-12	10-K	26-007497
34	current liabilities	us-gaap:LiabilitiesCurrent	$1.2B	2024-12-31	2026-02-12	10-K	26-007497
35	assets	us-gaap:Assets	$3.8B	2023-12-31	2025-02-13	10-K	25-000026
36	assets	us-gaap:Assets	$3.5B	2022-12-31	2024-02-15	10-K	24-000008
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	132,623,144	2026-02-06	2026-02-12	10-K	26-007497
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	129,457,156	2025-02-06	2025-02-13	10-K	25-000026

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.